Aktiesnakken — Juni 2010
-
præsentationen. I klinikken er han Konge
-
Det var også det han sagde til mig på GF

-
rth jeg har lavet et debat indlæg (Aabo får ret.....)
-
at markedet undervurderer zalut
-
LifeCycle Pharma A/S (OMX:LCP) meddeler i dag, at Edward E. Koval og Dr. John
Weinberg tiltræder LCP's ledelse som henholdvis Senior Vice President,
Business Development and Strategic Corporate Development, og Senior Vice
President, Commercial Developme -
merck, chiron, novartis baggrund
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind